Revance announces u.s. fda acceptance of supplemental biologics license application (sbla) for daxxify® (daxibotulinumtoxina-lanm) for injection for the treatment of cervical dystonia

Nashville, tenn.--( business wire )--revance therapeutics, inc. (nasdaq: rvnc) today announced that the u.s. food and drug administration (fda) has accepted for review a supplemental biologics license application (sbla) for daxxify® (daxibotulinumtoxina-lanm) for injection for the treatment of cervical dystonia in adults, a chronic and debilitating neurologic condition affecting the muscles of the neck.1 revance was provided a prescription drug user fee act (pdufa) date of august 19, 2023.
RVNC Ratings Summary
RVNC Quant Ranking